Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection

Dermatol Ther. 2020 Nov;33(6):e14159. doi: 10.1111/dth.14159. Epub 2020 Sep 9.

Abstract

Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients with human immunodeficiency virus. Herein, we describe the safe and successful use of dupilumab in a patient with atopic dermatitis, severe therapy resistant asthma, and HIV infection.

Keywords: HIV; asthma; atopic dermatitis; dupilumab.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized
  • Asthma* / diagnosis
  • Asthma* / drug therapy
  • Dermatitis, Atopic* / diagnosis
  • Dermatitis, Atopic* / drug therapy
  • HIV Infections* / complications
  • HIV Infections* / diagnosis
  • HIV Infections* / drug therapy
  • Humans
  • Interleukin-13
  • Male

Substances

  • Antibodies, Monoclonal, Humanized
  • Interleukin-13
  • dupilumab